{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283182","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.208296+00:00","generated_at":"2026-05-16T19:57:01.626575+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"enGene prices $130M public offering of common shares and pre-funded warrants","bullets":["Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.","Gross proceeds expected ~$130M before underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 2,294,117 additional common shares.","Offering expected to close on or about November 14, 2025.","Proceeds to advance clinical-stage genetic medicines pipeline, including lead NMIBC candidate detalimogene."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283182","json":"https://secwatch.observer/filing/0001193125-25-283182.json","markdown":"https://secwatch.observer/filing/0001193125-25-283182.md","text":"https://secwatch.observer/filing/0001193125-25-283182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/0001193125-25-283182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:57:01.626575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}